Broad-spectrum neuroprotection exerted by DDD-028 in a mouse model of chemotherapy-induced neuropathy
Authors:
- Elena LucariniELElena Lucarini
- Laura MicheliLMLaura Micheli
- Raghavan RajagopalanRRRaghavan Rajagopalan
- Clara CiampiCCClara Ciampi
- Jacopo J.V. BrancaJacopo J.V. Branca
- Alessandra PaciniAlessandra Pacini
- Massimo LeandriMLMassimo Leandri
- Parthasarathi RajagopalanPRParthasarathi Rajagopalan
- Carla GhelardiniCGCarla Ghelardini
- Lorenzo Di Cesare MannelliLorenzo Di Cesare Mannelli
Open Access
- 7 August 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 164 (11) , 2581-2595
Abstract
Neurotoxicity of chemotherapeutics involves peculiar alterations in the structure and function, including abnormal nerve signal transmission, of both the peripheral and central nervous system. The lack of effective pharmacological approaches to prevent chemotherapy-induced neurotoxicity necessitates the identification of innovative therapies. Recent evidence suggests that repeated treatment with the pentacyclic pyridoindole derivative DDD-028 can exert both pain-relieving and glial modulatory effects in mice with paclitaxel-induced neuropathy. This work is aimed at assessing whether DDD-028 is a disease-modifying agent by protecting the peripheral nervous tissues from chemotherapy-induced damage. Neuropathy was induced in animals by paclitaxel injection (2.0 mg kg −1 i.p). DDD-028 (10 mg kg −1 ) and the reference drug, pregabalin (30 mg kg −1 ), were administered per os daily starting concomitantly with the first injection of paclitaxel and continuing 10 days after the end of paclitaxel treatment. The behavioural tests confirmed the antihyperalgesic efficacy of DDD-028 on paclitaxel-induced neuropathic pain. Furthermore, the electrophysiological analysis revealed the capacity of DDD-028 to restore near-normal sensory nerve conduction in paclitaxel-treated animals. Histopathology evidence indicated that DDD-028 was able to counteract effectively paclitaxel-induced peripheral neurotoxicity by protecting against the loss of intraepidermal nerve fibers, restoring physiological levels of neurofilament in nerve tissue and plasma, and preventing morphological alterations occurring in the sciatic nerves and dorsal root ganglia. Overall, DDD-028 is more effective than pregabalin in preventing chemotherapy-induced neurotoxicity. Thus, based on its potent antihyperalgesic and neuroprotective efficacy, DDD-028 seems to be a viable prophylactic medication to limit the development of neuropathies consequent to chemotherapy.Keywords
This publication has 90 references indexed in Scilit:
- Assessment of Paclitaxel Induced Sensory Polyneuropathy with “Catwalk” Automated Gait Analysis in MicePLOS ONE, 2013
- Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancerNeurology, 2011
- Longitudinal assessment of oxaliplatin-induced neuropathyNeurology, 2011
- Terminal arbor degeneration - a novel lesion produced by the antineoplastic agent paclitaxelEuropean Journal of Neuroscience, 2011
- Intraepidermal nerve fiber loss corresponds to the development of Taxol-induced hyperalgesia and can be prevented by treatment with minocyclinePain, 2011
- Oxaliplatin-induced neuropathy in the rat: Involvement of oxalate in cold hyperalgesia but not mechanical allodyniaPain, 2009
- Mammalian Nicotinic Acetylcholine Receptors: From Structure to FunctionPhysiological Reviews, 2009
- An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the ratBrain Research, 2007
- Skin biopsy: a new tool for diagnosing peripheral neuropathyBMJ, 2007
- Paclitaxel- and vincristine-evoked painful peripheral neuropathies: Loss of epidermal innervation and activation of Langerhans cellsExperimental Neurology, 2006